Приказ основних података о документу

dc.creatorDžoljić, Eleonora
dc.creatorSarić-Matutinović, Marija
dc.creatorStojković, Oliver
dc.creatorVeličković, Jelena
dc.creatorMilinković, Neda
dc.creatorKostić, Vladimir
dc.creatorIgnjatović, Svetlana
dc.date.accessioned2023-10-31T14:01:23Z
dc.date.available2023-10-31T14:01:23Z
dc.date.issued2023
dc.identifier.issn0306-4522
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/5179
dc.description.abstractBackground: Vitamin D is a steroid hormone, known to be involved in the pathogenesis of various neurodegenerative disorders, including Parkinson's disease (PD). We aimed to clarify the relationship between hypovitaminosis D and the predisposition for PD and its clinical presentation. An additional aim was to examine the specific gene polymorphisms associated with vitamin D level. Material and methods: Total level of 25(OH)-vitamin D (25(OH)D) was measured in the serum of parkinsonian patients (n = 113) and controls (n = 82) using a commercial immunoassay. Genetic analyses were performed using Taqman assays on Real Time PCR amplification system. Results: Higher frequency of vitamin D deficiency (<50 nmol/L) was observed in PD patients, compared to controls (40.7% and 23.2%, respectively, P = 0.010). It was also a positive predictive marker of PD (OR, 2.27; 95% CI, 1.206–4.298; P < 0.011). Significantly higher UPDRS (35.85 ± 1.35 and 32.09 ± 0.99, respectively, P = 0.023) and HY scores (2(1.5–2.5) and 1.5(1.0–2.0), respectively, P = 0.005) were present in patients with 25(OH)D level < 50 nmol/L compared to patients with 25(OH)D level ≥ 50 nmol/L. Despite some trends observed, differences in allelic and genotypic distribution between controls and patients, as well as between subgroups, did not reach the level of significance (P > 0.05). Conclusions: Findings of this study confirm the hypothesis of a significant relationship between hypovitaminosis D and PD. We demonstrated higher prevalence of vitamin D deficiency in PD patients, as well as its predictive potential for the onset and progression of PD.
dc.publisherElsevier Ltd
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200161/RS//
dc.rightsrestrictedAccess
dc.sourceNeuroscience
dc.subjectParkinson's disease
dc.subject25(OH)-vitamin D
dc.subjectvitamin D
dc.subjectvitamin D deficiency
dc.titleVitamin D Serum Levels and Vitamin D Receptor Genotype in Patients with Parkinson's Disease
dc.typearticle
dc.rights.licenseARR
dc.citation.volume533
dc.citation.spage53
dc.citation.epage62
dc.citation.rankM22~
dc.identifier.doi10.1016/j.neuroscience.2023.10.004
dc.identifier.pmid37832907
dc.identifier.scopus2-s2.0-85174537476
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу